Fridays used to be reserved for routine headlines. But since Donald Trump’s reelection, every Friday seems like a bombshell day. And last Friday delivered a constitutional jolt to global trade. In a 6–3 ruling, the US Supreme Court struck down President Donald Trump’s use of emergency powers to impose sweeping tariffs, removing the executive “on-off
Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. The move comes as the drugmaker seeks to prepare for mounting sales pressure later this decade, driven by the looming loss of exclusivity for
Royal Bank of Canada stock has been in an unstoppable bull run in the past few years and is now hovering at its all-time high. It has soared by 160% in the last five years, beating JPMorgan, which has jumped by over 133% in the same period. So, will the rally accelerate as the company
Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to make that routine feel less like a chore. The company says it has launched a new Zepbound KwikPen
US equities were little changed on Monday after President Donald Trump announced an increase in global tariffs to 15%, following a Supreme Court ruling that struck down his earlier “reciprocal” tariff framework. The S&P 500 hovered around the flatline during the session, while the Dow Jones Industrial Average and the Nasdaq Composite also traded with
Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of €46.2 million, which was 357% more than its 2024 profit of €10.1 million. The Barcelona-based pharmaceutical company was able to exceed the significant €1 billion sales threshold thanks to a 12.5% increase in revenue to €1.1145 billion. Following a more muted
Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA’s approval for its treatment of schizophrenia and bipolar I disorder. The BYSANTI (milsaperidone) announcement is a welcome reprieve for VNDA that’s been under pressure this year as investors weighed “disappointing” Q4 earnings against a backdrop of
Nvidia stock (NASDAQ: NVDA) ticked higher on Monday as Wall Street headed into the chipmaker’s Feb. 25 earnings report with expectations already sky-high. The rally came as the analysts are modeling roughly $65 billion-plus in quarterly revenue, a level that would again underline how central Nvidia has become to AI infrastructure spending. The next two
Tesla stock (NASDAQ: TSLA) was higher on Friday, a notable divergence as Big Tech led a sharp selloff with investors debating whether the AI spending boom is starting to pressure near-term profits. The contrast matters because it suggests Tesla stock is being treated less like a simple “tech beta” trade and more like a stock
Pinterest Inc (NYSE: PINS) crashed more than 20% this morning after reporting a “disappointing” Q4 and offering current-quarter guidance that suggested things aren’t expected to improve anytime soon. And while the company’s management attributed much of this weakness to “tariffs,” Citi analysts believe there’s more at play here that could make it difficult for PINS